Skip to content
value.today

DermTech, Inc.: peers

Change the peers

DermTech, Inc. beside the 7 companies most like it by industry, size and country: every figure with its date and source, its rank in the group and its percentile in its sector and country.

DermTech, Inc., Accelerate Diagnostics, Inc.: the market cap on file is more than 60 days old or a last known value (no market-data feed for their exchanges yet), so their valuation multiples and yields are shown but not ranked.

Side by side#

Every figure with its fiscal year or date and its source. Switch to each company's rank in the group, or its percentile in its sector or country. How ranks are worked out.

DermTech, Inc., IB Acquisition Corp., Accelerate Diagnostics, Inc., DarioHealth Corp., Precipio, Inc., Star Equity Holdings, Inc., Sera Prognostics, Inc., Insight Molecular Diagnostics Inc. side by side: each figure with its period and source, its rank among these companies and its percentile in the company's sector and country
MeasureDermTech, Inc.base
DMTK · 🇺🇸 US
Percentile in Healthcare
Percentile in USA
IB Acquisition Corp.
IBAC · 🇺🇸 US
Percentile in Healthcare
Percentile in USA
Accelerate Diagnostics, Inc.
AXDX · 🇺🇸 US
Percentile in Healthcare
Percentile in USA
DarioHealth Corp.
DRIO · 🇺🇸 US
Percentile in Healthcare
Percentile in USA
Precipio, Inc.
PRPO · 🇺🇸 US
Percentile in Healthcare
Percentile in USA
Star Equity Holdings, Inc.
STRR · 🇺🇸 US
Percentile in Healthcare
Percentile in USA
Sera Prognostics, Inc.
SERA · 🇺🇸 US
Percentile in Healthcare
Percentile in USA
Insight Molecular Diagnostics Inc.
IMDX · 🇺🇸 US
Percentile in Healthcare
Percentile in USA
Group median
Size
Market cap (Better neither way: ranked highest first)$52 Mlast known, Jan 5, 2024 · Market dataLast known value: no current one5th of 8$55 MSep 28, 2026 · Market data4th of 8$58 Mlast known, Jan 5, 2024 · Market dataLast known value: no current one3rd of 8$42 MOct 22, 2026 · Market data6th of 8$38 MOct 22, 2026 · Market data7th of 8$37 MOct 15, 2026 · Market data8th of 8$82 MOct 30, 2026 · Market data2nd of 8$98 MOct 27, 2026 · Market data1st of 8$53 M8 ranked
Revenue (Better neither way: ranked highest first)————$12 MFY2024 · SEC4th of 6$22 MFY2025 · SEC3rd of 6$53 MFY2025 · SEC2nd of 6$172 MFY2025 · SEC1st of 6$0 MFY2025 · SEC6th of 6$4 MFY2025 · SEC5th of 6$17 M6 ranked
Net income (Higher is better)——$3 MFY2025 · SEC1st of 7$-50 MFY2024 · SEC6th of 7$-42 MFY2025 · SEC5th of 7$-0 MFY2025 · SEC2nd of 7$-6 MFY2025 · SEC3rd of 7$-32 MFY2025 · SEC4th of 7$-50 MFY2025 · SEC7th of 7$-32 M7 ranked
Employees (Better neither way: ranked highest first)————2752019 · Profile2nd of 4160March 11, 2026 · Profile3rd of 4——1,200December 31, 2025 · Profile1st of 472December 31, 2025 · Profile4th of 4——2184 ranked
Growth
Revenue growth (Higher is better)————————-3.0%FY2024 · SEC4th of 520th22nd-17.3%FY2025 · SEC5th of 511th7th+28.0%FY2025 · SEC2nd of 575th85th+22.9%FY2025 · SEC3rd of 572nd82nd————+116.0%FY2025 · SEC1st of 593rd97th+22.9%5 ranked
Revenue growth, 3 years a year (Higher is better)————————-0.2%FY2024 · SEC3rd of 527th32nd-6.8%FY2025 · SEC5th of 514th15th+38.1%FY2025 · SEC2nd of 585th94th-5.0%FY2025 · SEC4th of 517th18th————+61.7%FY2025 · SEC1st of 592nd97th-0.2%5 ranked
Earnings per share growth (Higher is better)————————————-17.5%FY2025 · SEConly one with it23rd23rd————————————————-17.5%—
Margins and returns
Gross margin (Higher is better)————————23.1%FY2024 · SEC4th of 512th24th56.6%FY2025 · SEC2nd of 548th70th20.0%FY2025 · SEC5th of 59th20th46.4%FY2025 · SEC3rd of 532nd60th————56.6%FY2025 · SEC1st of 548th70th46.4%5 ranked
Operating margin (Higher is better)————————-301.8%FY2024 · SEC4th of 411th4th-163.9%FY2025 · SEC3rd of 417th7th-2.2%FY2025 · SEC2nd of 455th36th-2.1%FY2025 · SEC1st of 455th36th————————-83.1%4 ranked
Net margin (Higher is better)————————-427.7%FY2024 · SEC4th of 47th2nd-186.5%FY2025 · SEC3rd of 416th7th-0.7%FY2025 · SEC1st of 459th41st-3.4%FY2025 · SEC2nd of 456th36th————————-95.0%4 ranked
Free cash flow margin (Higher is better)————————-211.1%FY2024 · SEC4th of 514th5th-116.6%FY2025 · SEC3rd of 520th7th0.7%FY2025 · SEC1st of 554th37th-5.2%FY2025 · SEC2nd of 544th25th————-624.6%FY2025 · SEC5th of 54th1st-116.6%5 ranked
Return on equity (Higher is better)————————————-59.6%FY2025 · SEC4th of 438th16th-2.7%FY2025 · SEC1st of 471st39th-11.2%FY2025 · SEC2nd of 466th32nd-51.8%FY2025 · SEC3rd of 442nd18th————-31.5%4 ranked
Valuation
P/E ratio (Better neither way: ranked highest first)————16.1×price Sep 28, 2026 · Market dataonly one with it23rd41st————————————————————————16.1×—
Price to sales (Better neither way: ranked highest first)————————————1.9×price Oct 22, 2026 · Market data2nd of 432nd48th0.6×price Oct 22, 2026 · Market data3rd of 411th19th0.2×price Oct 15, 2026 · Market data4th of 42nd4th————24.2×price Oct 27, 2026 · Market data1st of 485th95th1.3×4 ranked
Price to book (Better neither way: ranked highest first)————————————0.6×price Oct 22, 2026 · Market data3rd of 49th9th2.6×price Oct 22, 2026 · Market data1st of 444th57th0.6×price Oct 15, 2026 · Market data4th of 48th8th1.1×price Oct 30, 2026 · Market data2nd of 420th23rd————0.8×4 ranked
Free cash flow yield (Higher is better)————————————-62.8%price Oct 22, 2026 · Market data5th of 515th6th0.9%price Oct 22, 2026 · Market data1st of 572nd41st-24.2%price Oct 15, 2026 · Market data2nd of 530th13th-32.2%price Oct 30, 2026 · Market data4th of 525th11th-25.8%price Oct 27, 2026 · Market data3rd of 528th12th-25.8%5 ranked
Financial strength
Debt to equity (Lower is better)————————————0.5×FY2025 · SEC3rd of 351st40th0.0×FY2025 · SEC1st of 310th7th0.1×FY2025 · SEC2nd of 319th14th————————0.1×3 ranked
Net debt to EBITDA (Lower is better)————————————————-64.3×FY2025 · SEConly one with it0th0th————————————-64.3×—
Piotroski F-score (Higher is better)——————3 of 9FY2025 · SEC2nd of 37 of 9FY2025 · SEC1st of 31 of 9FY2025 · SEC3rd of 3————3.0 of 93 ranked
Scorecard
Scorecard (Higher is better)——3 of 6FY2025 · Scorecard2nd of 72 of 13FY2024 · Scorecard6th of 75 of 21FY2025 · Scorecard5th of 712 of 22FY2025 · Scorecard1st of 78 of 24FY2025 · Scorecard3rd of 72 of 14FY2025 · Scorecard7th of 75 of 17FY2025 · Scorecard4th of 729% passed7 ranked
Valuation checks (Higher is better)——2 of 3FY2025 · Scorecard1st of 6——2 of 5FY2025 · Scorecard2nd of 62 of 5FY2025 · Scorecard2nd of 62 of 5FY2025 · Scorecard2nd of 61 of 4FY2025 · Scorecard5th of 60 of 5FY2025 · Scorecard6th of 640% passed6 ranked
Growth checks (Higher is better)————1 of 6FY2024 · Scorecard3rd of 60 of 6FY2025 · Scorecard5th of 65 of 6FY2025 · Scorecard1st of 61 of 6FY2025 · Scorecard3rd of 60 of 3FY2025 · Scorecard5th of 64 of 6FY2025 · Scorecard2nd of 617% passed6 ranked
Profitability checks (Higher is better)——1 of 1FY2025 · Scorecard1st of 71 of 4FY2024 · Scorecard3rd of 71 of 5FY2025 · Scorecard4th of 72 of 5FY2025 · Scorecard2nd of 71 of 5FY2025 · Scorecard4th of 70 of 3FY2025 · Scorecard6th of 70 of 2FY2025 · Scorecard6th of 720% passed7 ranked
Financial health checks (Higher is better)——0 of 2FY2025 · Scorecard6th of 70 of 2FY2024 · Scorecard6th of 72 of 4FY2025 · Scorecard3rd of 73 of 5FY2025 · Scorecard1st of 73 of 5FY2025 · Scorecard1st of 71 of 3FY2025 · Scorecard4th of 71 of 3FY2025 · Scorecard4th of 733% passed7 ranked
Shareholder returns checks (Higher is better)————0 of 1FY2024 · Scorecard2nd of 60 of 1FY2025 · Scorecard2nd of 60 of 1FY2025 · Scorecard2nd of 61 of 3FY2025 · Scorecard1st of 60 of 1FY2025 · Scorecard2nd of 60 of 1FY2025 · Scorecard2nd of 60% passed6 ranked
Ownership
Held by institutions (Better neither way: ranked highest first)——0.7%2026-Q3 · 13FStill being filed: 98% of the filers of the quarter before are in6th of 6——15.1%2026-Q3 · 13FStill being filed: 98% of the filers of the quarter before are in5th of 615.5%2026-Q3 · 13FStill being filed: 98% of the filers of the quarter before are in4th of 625.0%2026-Q3 · 13FStill being filed: 98% of the filers of the quarter before are in3rd of 649.0%2026-Q3 · 13FStill being filed: 98% of the filers of the quarter before are in2nd of 656.7%2026-Q3 · 13FStill being filed: 98% of the filers of the quarter before are in1st of 620.3%6 ranked
Institutions holding (Better neither way: ranked highest first)——32026-Q3 · 13FStill being filed: 98% of the filers of the quarter before are in6th of 6——212026-Q3 · 13FStill being filed: 98% of the filers of the quarter before are in4th of 6202026-Q3 · 13FStill being filed: 98% of the filers of the quarter before are in5th of 6242026-Q3 · 13FStill being filed: 98% of the filers of the quarter before are in3rd of 6482026-Q3 · 13FStill being filed: 98% of the filers of the quarter before are in1st of 6442026-Q3 · 13FStill being filed: 98% of the filers of the quarter before are in2nd of 6236 ranked
Institutional holding, change over the quarter (Better neither way: ranked highest first)——0.0 pp2026-Q2 against 2026-Q1 · 13F4th of 5——+3.4 pp2026-Q2 against 2026-Q1 · 13F1st of 5+0.3 pp2026-Q2 against 2026-Q1 · 13F3rd of 5+0.8 pp2026-Q2 against 2026-Q1 · 13F2nd of 5——-2.5 pp2026-Q2 against 2026-Q1 · 13F5th of 5+0.3 pp5 ranked
Dividends
Shareholder yield (Higher is better)————————————————————7.1%FY2025 · SEConly one with it85th80th————————7.1%—

Under each figure: its fiscal year, quarter or date, and its source. ↑ higher is better, ↓ lower is better, · better neither way (ranked highest first). Ranks count only the companies with the figure; percentiles place each company among all the companies of its own sector and country with the figure (ten or more needed).

Sources: SEC = SEC annual reports (10-K, 20-F, 40-F); ESEF = ESEF annual reports (European and UK listed companies); Editors = The company's annual report, entered by value.today editors; Wikidata = Wikidata, citing the annual report; Scorecard = value.today scorecard: thirty checks on the company's statements, worked out daily; 13F = SEC Form 13F holdings reports; SEC = Dividends declared per share in SEC 10-Q and 10-K filings; Profile = The company's latest reported headcount; Market data = DermTech, Inc.: How market caps are worked out; IB Acquisition Corp.: SEC closing prices (fails-to-deliver files) times the shares on the latest 10-K or 10-Q cover; Accelerate Diagnostics, Inc.: SEC closing prices (fails-to-deliver files) times the shares on the latest 10-K or 10-Q cover; DarioHealth Corp.: SEC closing prices (fails-to-deliver files) times the shares on the latest 10-K or 10-Q cover; Precipio, Inc.: SEC closing prices (fails-to-deliver files) times the shares on the latest 10-K or 10-Q cover; Star Equity Holdings, Inc.: SEC closing prices (fails-to-deliver files) times the shares on the latest 10-K or 10-Q cover; Sera Prognostics, Inc.: SEC closing prices (fails-to-deliver files) times the shares on the latest 10-K or 10-Q cover; Insight Molecular Diagnostics Inc.: SEC closing prices (fails-to-deliver files) times the shares on the latest 10-K or 10-Q cover.

Where each stands in its sector and country: Operating margin#

The dot is the company; the line runs from the 10th to the 90th percentile of all the companies of its sector (or country) with the figure, the box holds the middle half and the tick is the median. Each company's newest fiscal year; figures that divide by the market value only with a market cap at most 60 days old. How percentiles are worked out.

Operating margin: each company's figure and its percentile in its sector and its country
CompanyOperating marginIn its sectorIn its country
DermTech, Inc.———
IB Acquisition Corp.———
Accelerate Diagnostics, Inc.-301.8%FY2024
11th percentile in Healthcaremedian -7.7%, 674 companies
4th percentile in USAmedian 3.5%, 2,594 companies
DarioHealth Corp.-163.9%FY2025
17th percentile in Healthcaremedian -7.7%, 674 companies
7th percentile in USAmedian 3.5%, 2,594 companies
Precipio, Inc.-2.2%FY2025
55th percentile in Healthcaremedian -7.7%, 674 companies
36th percentile in USAmedian 3.5%, 2,594 companies
Star Equity Holdings, Inc.-2.1%FY2025
55th percentile in Healthcaremedian -7.7%, 674 companies
36th percentile in USAmedian 3.5%, 2,594 companies
Sera Prognostics, Inc.———
Insight Molecular Diagnostics Inc.———

Revenue by fiscal year, and the rank in the group#

Revenue of the fiscal year. US dollars at each year's exchange rate; fiscal years as each company names them. Ranks: 1st is the highest (better neither way).

Revenue

$0 M$233 M$467 M$700 M$934 M20102012201420162018202020222024Accelerate Diagnostics, Inc. $12 MDarioHealth Corp. $22 MPrecipio, Inc. $53 MStar Equity Holdings, Inc. $172 MSera Prognostics, Inc. $0 MInsight Molecular Diagnostics Inc. $4 M

Rank in the group

1st2nd3rd4th5th6th201120122013201420152016201720182019202020212022202320242025Accelerate Diagnostics, Inc.: 3rd of 3 in 2011Accelerate Diagnostics, Inc.: 3rd of 3 in 2012Accelerate Diagnostics, Inc.: 3rd of 3 in 2013Accelerate Diagnostics, Inc.: 3rd of 4 in 2014Accelerate Diagnostics, Inc.: 4th of 4 in 2015Accelerate Diagnostics, Inc.: 4th of 4 in 2016Accelerate Diagnostics, Inc.: 3rd of 4 in 2017Accelerate Diagnostics, Inc.: 3rd of 4 in 2018Accelerate Diagnostics, Inc.: 2nd of 4 in 2019Accelerate Diagnostics, Inc.: 3rd of 6 in 2020Accelerate Diagnostics, Inc.: 4th of 6 in 2021Accelerate Diagnostics, Inc.: 4th of 6 in 2022Accelerate Diagnostics, Inc.: 4th of 6 in 2023Accelerate Diagnostics, Inc.: 4th of 6 in 2024Accelerate Diagnostics, InDarioHealth Corp.: 4th of 4 in 2014DarioHealth Corp.: 3rd of 4 in 2015DarioHealth Corp.: 2nd of 4 in 2016DarioHealth Corp.: 2nd of 4 in 2017DarioHealth Corp.: 2nd of 4 in 2018DarioHealth Corp.: 4th of 4 in 2019DarioHealth Corp.: 4th of 6 in 2020DarioHealth Corp.: 2nd of 6 in 2021DarioHealth Corp.: 2nd of 6 in 2022DarioHealth Corp.: 3rd of 6 in 2023DarioHealth Corp.: 3rd of 6 in 2024DarioHealth Corp.: 3rd of 5 in 2025DarioHealth Corp.Precipio, Inc.: 2nd of 3 in 2011Precipio, Inc.: 2nd of 3 in 2012Precipio, Inc.: 2nd of 3 in 2013Precipio, Inc.: 2nd of 4 in 2014Precipio, Inc.: 2nd of 4 in 2015Precipio, Inc.: 3rd of 4 in 2016Precipio, Inc.: 4th of 4 in 2017Precipio, Inc.: 4th of 4 in 2018Precipio, Inc.: 3rd of 4 in 2019Precipio, Inc.: 2nd of 6 in 2020Precipio, Inc.: 3rd of 6 in 2021Precipio, Inc.: 3rd of 6 in 2022Precipio, Inc.: 2nd of 6 in 2023Precipio, Inc.: 2nd of 6 in 2024Precipio, Inc.: 2nd of 5 in 2025Precipio, Inc.Star Equity Holdings, Inc.: 1st of 3 in 2011Star Equity Holdings, Inc.: 1st of 3 in 2012Star Equity Holdings, Inc.: 1st of 3 in 2013Star Equity Holdings, Inc.: 1st of 4 in 2014Star Equity Holdings, Inc.: 1st of 4 in 2015Star Equity Holdings, Inc.: 1st of 4 in 2016Star Equity Holdings, Inc.: 1st of 4 in 2017Star Equity Holdings, Inc.: 1st of 4 in 2018Star Equity Holdings, Inc.: 1st of 4 in 2019Star Equity Holdings, Inc.: 1st of 6 in 2020Star Equity Holdings, Inc.: 1st of 6 in 2021Star Equity Holdings, Inc.: 1st of 6 in 2022Star Equity Holdings, Inc.: 1st of 6 in 2023Star Equity Holdings, Inc.: 1st of 6 in 2024Star Equity Holdings, Inc.: 1st of 5 in 2025Star Equity Holdings, Inc.Sera Prognostics, Inc.: 6th of 6 in 2020Sera Prognostics, Inc.: 6th of 6 in 2021Sera Prognostics, Inc.: 6th of 6 in 2022Sera Prognostics, Inc.: 6th of 6 in 2023Sera Prognostics, Inc.: 6th of 6 in 2024Sera Prognostics, Inc.: 5th of 5 in 2025Sera Prognostics, Inc.Insight Molecular Diagnostics Inc.: 5th of 6 in 2020Insight Molecular Diagnostics Inc.: 5th of 6 in 2021Insight Molecular Diagnostics Inc.: 5th of 6 in 2022Insight Molecular Diagnostics Inc.: 5th of 6 in 2023Insight Molecular Diagnostics Inc.: 5th of 6 in 2024Insight Molecular Diagnostics Inc.: 4th of 5 in 2025Insight Molecular Diagnost
Revenue by fiscal year with each company's rank in the group and the source of each figure
Fiscal yearDermTech, Inc.IB Acquisition Corp.Accelerate Diagnostics, Inc.DarioHealth Corp.Precipio, Inc.Star Equity Holdings, Inc.Sera Prognostics, Inc.Insight Molecular Diagnostics Inc.
2025———$22 MSEC3rd$53 MSEC2nd$172 MSEC1st$0 MSEC5th$4 MSEC4th
2024——$12 MSEC4th$27 MSEC3rd$42 MSEC2nd$140 MSEC1st$0 MSEC6th$2 MSEC5th
2023——$12 MSEC4th$20 MSEC3rd$30 MSEC2nd$161 MSEC1st$0 MSEC6th$2 MSEC5th
2022——$13 MSEC4th$28 MSEC2nd$20 MSEC3rd$201 MSEC1st$0 MSEC6th$1 MSEC5th
2021——$12 MSEC4th$21 MSEC2nd$18 MSEC3rd$169 MSEC1st$0 MSEC6th$2 MSEC5th
2020——$11 MSEC3rd$8 MSEC4th$16 MSEC2nd$101 MSEC1st$0 MSEC6th$1 MSEC5th
2019——$9 MSEC2nd$8 MSEC4th$8 MSEC3rd$94 MSEC1st——
2018——$6 MSEC3rd$7 MSEC2nd$5 MSEC4th$67 MSEC1st——
2017——$4 MSEC3rd$5 MSEC2nd$3 MSEC4th$457 MSEC1st——
2016——$0 MSEC4th$3 MSEC2nd$2 MSEC3rd$423 MSEC1st——
2015——$0 MSEC4th$1 MSEC3rd$2 MSEC2nd$463 MSEC1st——
2014——$0 MSEC3rd$0 MSEC4th$1 MSEC2nd$581 MSEC1st——

Sources: SEC = SEC annual reports (10-K, 20-F, 40-F); ESEF = ESEF annual reports (European and UK listed companies); Ed. = The company's annual report, entered by value.today editors; WD = Wikidata, citing the annual report; Cap = value.today market caps (the last of each calendar year). The small ordinal is the rank in the group that year. Hover a figure for its fiscal year end.

Suggested peers of DermTech, Inc.#

Companies of the same industry, within a hundred times its size (market cap), scored out of 100 for industry, size, country and figures on file. How peers are suggested.

  • IB Acquisition Corp.IBAC · 🇺🇸 USA
    Same industry: Diagnostics and Research · Similar size: $55 M market cap against $52 M · Same country: USA · Ratios of the last two fiscal years on file
    Market cap $55 M (Sep 28, 2026)
    100 of 100 (industry or sector 50 + size 30 + country 15 + figures on file 5)
    In the group
  • Accelerate Diagnostics, Inc.AXDX · 🇺🇸 USA
    Same industry: Diagnostics and Research · Similar size: $58 M market cap against $52 M · Same country: USA · Ratios of the last two fiscal years on file
    Market cap $58 M (last known, Jan 5, 2024) · revenue $12 M (year to December 2024)
    99 of 100 (industry or sector 50 + size 29 + country 15 + figures on file 5)
    In the group
  • DarioHealth Corp.DRIO · 🇺🇸 USA
    Same industry: Diagnostics and Research · Similar size: $42 M market cap against $52 M · Same country: USA · Ratios of the last two fiscal years on file
    Market cap $42 M (Oct 22, 2026) · revenue $22 M (year to December 2025)
    98 of 100 (industry or sector 50 + size 29 + country 15 + figures on file 5)
    In the group
  • Precipio, Inc.PRPO · 🇺🇸 USA
    Same industry: Diagnostics and Research · Similar size: $38 M market cap against $52 M · Same country: USA · Ratios of the last two fiscal years on file
    Market cap $38 M (Oct 22, 2026) · revenue $53 M (year to December 2025)
    98 of 100 (industry or sector 50 + size 28 + country 15 + figures on file 5)
    In the group
  • Star Equity Holdings, Inc.STRR · 🇺🇸 USA
    Same industry: Diagnostics and Research · Similar size: $37 M market cap against $52 M · Same country: USA · Ratios of the last two fiscal years on file
    Market cap $37 M (Oct 15, 2026) · revenue $172 M (year to December 2025)
    98 of 100 (industry or sector 50 + size 28 + country 15 + figures on file 5)
    In the group
  • Sera Prognostics, Inc.SERA · 🇺🇸 USA
    Same industry: Diagnostics and Research · Similar size: $82 M market cap against $52 M · Same country: USA · Ratios of the last two fiscal years on file
    Market cap $82 M (Oct 30, 2026) · revenue $0 M (year to December 2025)
    97 of 100 (industry or sector 50 + size 27 + country 15 + figures on file 5)
    In the group
  • Insight Molecular Diagnostics Inc.IMDX · 🇺🇸 USA
    Same industry: Diagnostics and Research · Similar size: $98 M market cap against $52 M · Same country: USA · Ratios of the last two fiscal years on file
    Market cap $98 M (Oct 27, 2026) · revenue $4 M (year to December 2025)
    96 of 100 (industry or sector 50 + size 26 + country 15 + figures on file 5)
    In the group
  • Anixa Biosciences, Inc.ANIX · 🇺🇸 USA
    Same industry: Diagnostics and Research · Similar size: $117 M market cap against $52 M · Same country: USA · Ratios of the last two fiscal years on file
    Market cap $117 M (Oct 29, 2026)
    95 of 100 (industry or sector 50 + size 25 + country 15 + figures on file 5)
    + Add
  • Aspira Women's Health Inc.AWH · 🇺🇸 USA
    Same industry: Diagnostics and Research · Similar size: $46 M market cap against $52 M · Same country: USA
    Market cap $46 M (last known, Jan 5, 2024)
    94 of 100 (industry or sector 50 + size 29 + country 15)
    + Add
  • Enzo Biochem, Inc.ENZ · 🇺🇸 USA
    Same industry: Diagnostics and Research · Similar size: $72 M market cap against $52 M · Same country: USA
    Market cap $72 M (last known, Jan 5, 2024) · revenue $76 M
    93 of 100 (industry or sector 50 + size 28 + country 15)
    + Add
  • MaxCyte, Inc.MXCT · 🇺🇸 USA
    Same industry: Diagnostics and Research · Similar size: $156 M market cap against $52 M · Same country: USA · Ratios of the last two fiscal years on file
    Market cap $156 M (Oct 27, 2026) · revenue $33 M (year to December 2025)
    93 of 100 (industry or sector 50 + size 23 + country 15 + figures on file 5)
    + Add
  • Neuronetics, Inc.STIM · 🇺🇸 USA
    Same industry: Diagnostics and Research · Similar size: $162 M market cap against $52 M · Same country: USA · Ratios of the last two fiscal years on file
    Market cap $162 M (Oct 23, 2026) · revenue $149 M (year to December 2025)
    93 of 100 (industry or sector 50 + size 23 + country 15 + figures on file 5)
    + Add

Any figure over the years, other peers or a saved group: open this group in the peer workspace.